European Union - English - EMA (European Medicines Agency)

baxalta innovations gmbh - pegaspargase - precursor cell lymphoblastic leukemia-lymphoma - antineoplastic agents, - oncaspar is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (all) in paediatric patients from birth to 18 years, and adult patients.,

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

holcus lanatus) pollen 50hep/ml solution for skin prick test (inmunotek - yorkshire fog (velvet grass, holcus lanatus) pollen allergen extract - solution for skin-prick test

Ireland - English - HPRA (Health Products Regulatory Authority)

shire pharmaceutical contracts ltd - lisdexamfetamine dimesylate - capsules hard - 20 milligram - phenylethylamine derivatives - centrally acting sympathomimetics - it is indicated as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (adhd) in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate

Ireland - English - HPRA (Health Products Regulatory Authority)

shire pharmaceutical contracts ltd - lisdexamfetamine dimesylate - capsules hard - 40 milligram - phenylethylamine derivatives - centrally acting sympathomimetics - it is indicated as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (adhd) in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate

Ireland - English - HPRA (Health Products Regulatory Authority)

shire pharmaceutical contracts ltd - lisdexamfetamine dimesylate - capsules hard - 60 milligram - phenylethylamine derivatives - centrally acting sympathomimetics - it is indicated as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (adhd) in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate.

European Union - English - EMA (European Medicines Agency)

shire pharmaceutical contracts limited - epoetin delta - kidney failure, chronic; anemia - antianemic preparations - dynepo is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult patients. it may be used in patients on dialysis and in patients not on dialysis.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

allergy therapeutics (uk) ltd - yorkshire fog (velvet grass, holcus lanatus) pollen allergen extract; sweet vernal (anthoxanthum odoratum) pollen allergen extract; rye grass (lolium perenne) pollen allergen extract; dogstail (cynosurus cristatus) pollen allergen extract; tall fescue (meadow fescue, festuca pratensis) pollen allergen extract; cocksfoot (orchard grass, dactylis glomerata) pollen allergen extract; brome (bromus species) pollen allergen extract; bent (agrostis capillaris) pollen allergen extract; meadow foxtail (alopecurus pratensis) pollen allergen extract; timothy grass (phleum pratense) pollen allergen extract; false oat grass (arrhenatherum elatius) pollen allergen extract; meadow grass (kentucky blue grass, poa pratensis) pollen allergen extract - solution for skin-prick test

Ireland - English - HPRA (Health Products Regulatory Authority)

shire pharmaceutical contracts ltd - lanthanum carbonate hydrate - tablets chewable - 500 milligram - drugs for treatment of hyperkalemia and hyperphosphatemia

Ireland - English - HPRA (Health Products Regulatory Authority)

shire pharmaceutical contracts ltd - lanthanum carbonate hydrate - tablets chewable - 250 milligram - drugs for treatment of hyperkalemia and hyperphosphatemia

Ireland - English - HPRA (Health Products Regulatory Authority)

shire pharmaceutical contracts ltd - lanthanum carbonate hydrate - tablets chewable - 1000 milligram - drugs for treatment of hyperkalemia and hyperphosphatemia